Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2003;34:1015-1020
Published online before print March 20, 2003, doi: 10.1161/01.STR.0000063404.27912.5B
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
34/4/1015    most recent
01.STR.0000063404.27912.5Bv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Horiguchi, T.
Right arrow Articles by Busija, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horiguchi, T.
Right arrow Articles by Busija, D. W.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*3-NITROPROPIONIC ACID
Medline Plus Health Information
*Transient Ischemic Attack
Related Collections
Right arrow Animal models of human disease
Right arrow Acute Cerebral Infarction
Right arrow Neuroprotectors

(Stroke. 2003;34:1015.)
© 2003 American Heart Association, Inc.


Original Contributions

Opening of Mitochondrial ATP-Sensitive Potassium Channels Is a Trigger of 3-Nitropropionic Acid–Induced Tolerance to Transient Focal Cerebral Ischemia in Rats

Takashi Horiguchi, MD; Bela Kis, PhD; Nishadi Rajapakse, BS; Katsuyoshi Shimizu, MD David W. Busija, PhD

From the Department of Physiology and Pharmacology (T.H., B.K., N.R., D.W.B.) and Molecular Medicine Graduate Program (N.R.), Wake Forest University School of Medicine, Winston-Salem, NC, and Department of Neurosurgery, Tachikawa Hospital, Tokyo, Japan (K.S.).

Correspondence to Takashi Horiguchi, MD, Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1083. E-mail takaholy{at}aol.com


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background and Purpose— The role of mitochondrial ATP-sensitive potassium channels (mitoKATP) in ischemic tolerance has been well documented in heart, but little work has been done in brain. To investigate the involvement of mitoKATP activation in chemical preconditioning in brain, we examined the effect of 5-hydroxydecanoate (5-HD), a selective mitoKATP blocker, on neurotoxin 3-nitropropionic acid (3-NPA)–induced ischemic tolerance to transient focal cerebral ischemia in rats.

Methods— Male Wistar rats were administrated 3-NPA (20 mg/kg IP; n=16) or vehicle (saline; n=16) 3 days before temporary occlusion (120 minutes) of the middle cerebral artery; 5-HD (40 mg/kg IP; n=16) was injected 20 minutes before 3-NPA administration. Infarct volumes were measured 4 days after reperfusion. To directly investigate whether chemical preconditioning activates mitoKATP, we tested the effect of prior incubation with 1 mmol/L 5-HD on 300 µmol/L 3-NPA–induced alterations of mitochondrial membrane potential ({Delta}{Psi}m) in cultured neurons and astrocytes using the fluorescent dye tetramethylrhodamine ethyl ester.

Results— Treatment with 3-NPA exhibited a 16% reduction (P<0.05) and 23% reduction in infarct volume (P<0.01) for total brain and cortex, respectively. Pretreatment with 5-HD completely abolished the neuroprotective effect of chemical preconditioning. In cultured cells, 3-NPA resulted in mitochondrial depolarization. This change of {Delta}{Psi}m was completely blocked by 5-HD pretreatment.

Conclusions— These results strongly suggest that opening of mitoKATP plays a key role as the trigger in the development of 3-NPA–induced ischemic tolerance in brain.


Key Words: brain ischemia • middle cerebral artery occlusion • mitochondria • potassium channels • rats


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Ischemic tolerance" is a phenomenon in which preconditioning with sublethal stresses or stimuli such as brief ischemia,1 spreading depression,2 or pharmacological agents3 can induce resistance to subsequent lethal ischemia. It is clear in the heart and brain that activation of ATP-sensitive potassium channels (KATP) is an essential initiator of the mechanisms resulting in the development of ischemic tolerance.4,5 KATP are found in many places within cells, including the surface membrane (sKATP) and the inner mitochondrial membrane (mitoKATP), which have different pharmacological and functional properties.6 Recently, in heart, a pivotal role of mitoKATP in development of ischemic tolerance was established.7 In contrast, the correlation between mitoKATP and ischemic tolerance in the brain has been relatively unstudied. Recent studies have revealed that diazoxide, a selective agonist of mitoKATP, applied approximately 30 minutes before index ischemia, ameliorates neuronal dysfunction and damage.8–10 However, the role of mitoKATP in delayed tolerance, which appears 24 to 72 hours after preconditioning, is unclear and apparently unstudied in brain.

Fungal toxin 3-nitropropionic acid (3-NPA) has direct effects on mitochondria as the inhibitor of succinate dehydrogenase, associated with the tricarboxylic acid cycle and complex II in the respiratory chain.11 In the brain, the striatum is the most vulnerable region to systemic intoxication with high doses12 or repeated injections of low-dose 3-NPA.13 On the other hand, several studies have shown that a single dose of 20 mg/kg 3-NPA given systemically confers no histopathological abnormalities but provides delayed cerebral ischemic tolerance.3,12,14,15 Although a previous study reported that 3-NPA has the potential to activate sKATP in hippocampal cells,16 the role of mitoKATP in mediating the delayed ischemic tolerance with 3-NPA has not been documented in intact brain. The purpose of this study was to examine the involvement of mitoKATP opening in the generation of delayed ischemic tolerance with 3-NPA in brain. We tested whether the selective KATP blocker glibenclamide or selective mitoKATP blocker 5-hydroxydecanoate (5-HD) would prevent delayed protection by 3-NPA in rats after transient middle cerebral artery occlusion (MCAO). To directly investigate whether chemical preconditioning with 3-NPA induces opening of mitoKATP, we examined the effects of 5-HD on alterations of mitochondrial membrane potential ({Delta}{Psi}m) produced by 3-NPA in cultured neurons.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Animals
We used 88 male Wistar rats (weight, 250 to 320 g) for the MCAO experiments and embryonic day-18 Wistar rats for culturing neurons. All animal protocols were approved by the institutional animal care and use committee.

Focal Cerebral Ischemia
Transient focal cerebral ischemia was induced by the MCAO filament model as previously described with some modifications.17 Briefly, rats were fasted overnight with free access to water before surgery. After anesthesia was induced with 5% halothane in oxygen, rats were ventilated spontaneously with 1.0% halothane in a 70:30 gas mixture of N2O and O2. The tail artery was cannulated to monitor mean blood pressure, blood sugar, and blood gases. During surgery, the rectal temperature was maintained in a range between 36.5°C and 37.5°C by a heating pad. The right external and internal carotid arteries (ECA and ICA, respectively) were dissected from surrounding connective tissue through a midline neck incision. The branches of the ECA were ligated and cut. Then the ECA was cut between the double ligations at the distal portion. Two microvascular clips were placed across the common carotid artery and the ICA. A 4-0 monofilament nylon suture (Ethicon), its tip coated with silicon (Rhodoia RTV 1556 A and B), was introduced into the ICA via the ECA stump gently and advanced in the ICA approximately 20 mm from the carotid bifurcation after the proximal microvascular clip was removed. The suture around the ECA stump was tightened. After the incision was closed, anesthesia was discontinued, and rats were kept in the cage during 120 minutes of MCAO. The animals were reanesthetized 2 hours after induction of ischemia to remove the suture and to ligate the stump of the ECA. After reperfusion, rats were awakened quickly, kept in the cage, and allowed free access to food and water. In several rats, local cerebral blood flow (CBF) of the assumed infarct core was measured with laser-Doppler flowmetry (Multichannel Laser Doppler System, PERIMED). The bone of the skull was drilled out at 0.5 mm posterior and 4.5 mm lateral to the bregma without injuring the dura under the surgical microscope. Local CBF was measured at 4 time points, ie, before ischemia (baseline), just after insertion of the occluder, just before reperfusion, and after reperfusion. Four days after recovery from MCAO, all animals were anesthetized with halothane 5% in O2 and decapitated.

Measurement of Infarct Volume
The rat brain was quickly removed and sliced into coronal sections at 2-mm intervals. Each slice was immersed in a 2% solution of 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma) for 20 minutes and then fixed in 10% buffered formaldehyde solution. The infarction area in each brain slice was determined on the NIH Image program (version 1.62) according to the indirect method proposed by Swanson and others.18 Total infarct volumes in cortex and basal ganglia expressed in cubic millimeters were calculated by summation of the infarcted area in 6 brain slices (2 to 14 mm from frontal pole) and integrated by the thickness (2 mm).

Experimental Design
The rats were randomly assigned to 1 of the following 5 groups (Figure 1). A single dose of 20 mg/kg 3-NPA is documented to confer significant neuroprotection but not abnormalities in neurological and histopathological outcomes.3,12,14,15 In group 1 (n=32), animals were chemically preconditioned with 3-NPA (Sigma; 20 mg/kg, diluted in sodium chloride 0.9% to a concentration of 1 mg/mL, buffered [pH 7.4] with NaOH, IP) 24 hours (n=8), 48 hours (n=8), or 72 hours (n=16) before MCAO. In the following groups, all drugs were given 72 hours before MCAO. Group 2 (n=16) consisted of rats injected with only saline (sodium chloride 0.9%, IP). In group 3 (n=16), animals received glibenclamide (Sigma; 0.1 mg/kg, dissolved in 20 µL dimethyl sulfoxide) into the left lateral ventricle under stereotaxic guidance as described by Nishimura et al19 20 minutes before 3-NPA administration. In group 4 (n=16), animals were treated with 5-HD (Sigma; 40 mg/kg, in sodium chloride 0.9% to a concentration of 1 mg/mL, buffered [pH 7.4] with NaOH, IP) 20 minutes before administration of 3-NPA. Group 5 (n=16) represented rats treated with 5-HD alone.



View larger version (28K):
[in this window]
[in a new window]
 
Figure 1. Experimental protocol indicating time of drug application, induction of index ischemia, and TTC staining.

Cell Culture
Primary rat cortical neurons were cultured on the basis of the method of Deadwyler et al.20,21 Pregnant Wistar rats were anesthetized with pentobarbital (50 mg/kg), and E18 fetuses were recovered by caesarian section. After brains were removed from the fetuses, the pial membranes were peeled off. The collected cortical pieces were placed in ice-cold Dulbecco’s modified Eagle’s medium (DMEM) (Gibco BRL) and incubated with dispase I (2 U/mL; Roche) for 35 minutes at 37°C after they were washed twice in DMEM supplemented with penicillin (100 U/mL; Sigma) and streptomycin (100 µg/mL; Sigma). The cells were washed twice with DMEM to stop the enzymatic reaction and then were dissociated by 2 series of gentle trituration via 200- and 20-µL pipette tips and plated at a density of 105 cells per square centimeter onto poly-D-lysine–coated glass coverslips (Becton-Dickinson); they were maintained in Neurobasal medium (Gibco BRL) supplemented with B27 (2%; Gibco BRL), L-glutamine (0.5 mmol/L; Sigma), ß-mercaptoethanol (55 µmol/L; Gibco BRL), and potassium chloride (25 mmol/L). Cultures were grown at 37°C in a humidified atmosphere containing 5% CO2 in air, and medium was changed on every third day. Cultures consisted of >98% of neurons verified by positive immunostaining for microtubule-associated protein-2 (Becton-Dickinson) and negative immunostaining for glial fibrillary acidic protein (Chemicon). Cells were used for experiments at 7 to 9 days in vitro.

Analysis of Mitochondrial Membrane Potential
We monitored {Delta}{Psi}m using the {Delta}{Psi}m-sensitive dye tetramethylrhodamine ethyl ester (TMRE) (Molecular Probes). Neuronal cultures were loaded in the dark at 37°C in the 5% CO2 incubator with 0.5 µmol/L TMRE in Neurobasal medium for 15 minutes. After they were loaded, the cells were washed 3 times with phosphate-buffered saline, and cell cultures were then placed on the stage of the confocal microscope in phosphate-buffered saline. Experiments were performed at 22°C. Confocal images of cellular TMRE fluorescence were acquired on a Zeiss LSM 510 laser scanning microscope with the use of a x63, numerical aperture 1.2, Zeiss C-Apochromat water immersion objective. Fields of cells were randomly selected under differential interference contrast optics. The cells were treated with 3-NPA (300 µmol/L) with or without prior incubation with 5-HD (1 mmol/L) for 1 minute, and fluorescent images were obtained with excitation {lambda}=543 and emission {lambda} >560 nm (560 nm long-pass filter). Images were recorded every minute for 5 minutes after treatment, and the average pixel intensity in individual cell bodies was determined with the use of a computerized image analysis system (NIH Image, version 1.62). The estimated brain concentration after systemic administration of 20 mg/kg 3-NPA is 300 µmol/L.3 Additionally, to confirm that 3-NPA–induced cellular consequences occurred in mitochondria, we also used the mitochondrion-selective dye chloromethyl-tetramethyl-rosamine (CMTMROS) (MitoTracker Orange, Molecular Probes) with the same confocal microscope. Cultured cells were loaded with 2 µmol/L CMTMROS in Neurobasal medium for 20 minutes. Then the cells were rinsed 3 times with phosphate-buffered saline. Fluorescent images at before and 5 minutes after 3-NPA application were obtained with or without 5-HD preincubation, at excitation {lambda}=554 and emission {lambda} >576 nm.

Statistical Analysis
All data are expressed as mean±SEM. A 1-way ANOVA followed by the Fisher least significant difference test was performed to assess statistical differences for infarct volumes, physiological parameters, and local CBF. To compare the change of {Delta}{Psi}m, a 2-tailed unpaired t test was performed. A probability value <0.05 was regarded as statistically significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
Physiological Parameters
The physiological parameters during surgery among the 5 groups showed no statistically significant differences (Table 1).


View this table:
[in this window]
[in a new window]
 
TABLE 1. Physiological Parameters of Rats Before and After Surgery

Cerebral Blood Flow
Local CBF during MCAO showed no significant differences among the 5 groups (Table 2).


View this table:
[in this window]
[in a new window]
 
TABLE 2. Local Cerebral Blood Flow During MCAO

Infarct Volume
Pretreatment with 3-NPA at an interval of 24 hours (n=8) or 48 hours (n=8) before MCAO had no protective effect (infarct volume of 291.7±47.7 and 299.6±47.1 mm3 for 24 and 48 hours, respectively) (Figure 2). Only administration of 3-NPA 72 hours before MCAO consistently decreased infarct volume; the reduction in infarct volume for total brain was 16% and for the cortex was 23%. The subcortical infarct volumes were not significantly different. The administration of glibenclamide or 5-HD completely abolished the protective effect of 3-NPA. Treatment with 5-HD alone did not aggravate ischemic damage.



View larger version (36K):
[in this window]
[in a new window]
 
Figure 2. Glibenclamide (Glib) or 5-HD abolished 3-NPA–induced ischemic tolerance. A, Treatment of 3-NPA 72 hours before ischemia induced significant protective effect in cerebral cortex but not in subcortical area. Glibenclamide or 5-HD completely abolished 3-NPA–induced ischemic tolerance. Data are mean±SEM. *P<0.05 vs vehicle; **P<0.01 vs vehicle. B, Effect of 5-HD on 3-NPA–induced reduction of cortical infarct area. Data are mean±SEM. *P<0.05 vs 3-NPA; #P<0.05 vs vehicle.

Mitochondrial Membrane Potential
Administration of 3-NPA decreased {Delta}{Psi}m (representing depolarization), as shown by the increment of TMRE fluorescence intensity in neurons (Figure 3). The measured fluorescence intensity of TMRE immediately increased after exposure to 3-NPA and reached a maximum by 1 minute in neurons before decreasing toward baseline values at 2 to 5 minutes (Figure 3A, gray bars). Pretreatment of 5-HD significantly prevented the mitochondrial depolarization in cultured neurons (Figure 3A, solid bars).



View larger version (66K):
[in this window]
[in a new window]
 
Figure 3. 3-NPA–induced mitochondrial membrane depolarization in neurons was completely inhibited by selective mitoKATP blocker 5-HD. A, Temporal profile of alterations of TMRE fluorescence intensity. Fluorescence intensity immediately increased after exposure to 3-NPA and reached a maximum by 1 minute. At 2 minutes after 3-NPA application, fluorescence intensity began to decrease toward baseline values (gray bars). Pretreatment with 5-HD significantly inhibited 3-NPA–induced alterations of TMRE fluorescence intensity (solid bars). *P<0.01. B, Representative confocal micrographs of 3-NPA–treated neurons with or without 5-HD pretreatment using TMRE. Top row, Before 3-NPA application, TMRE accumulated in mitochondria because of its negative charge (Before). One minute after 3-NPA exposure, fluorescence intensity increased in the cytoplasm because of depolarization-induced TMRE release from mitochondria. Three minutes after, TMRE fluorescence intensity began to decrease in the cytoplasm. At 5 minutes, fluorescence was detected in the same intracellular location as seen before 3-NPA treatment. Bottom row, 5-HD completely inhibited 3-NPA–induced {Delta}{Psi}m depolarization. C, Representative confocal micrographs of 3-NPA–treated neurons with or without 5-HD pretreatment using CMTMROS. Pretreatment with 5-HD completely inhibited 3-NPA–induced change of CMTMROS fluorescence intensity. Bar=10 µm.

The representative photographs in Figure 3B demonstrate the changes of intracellular distribution of TMRE fluorescence induced by 3-NPA in neurons. Before application of 3-NPA, TMRE fluorescence was detected in mitochondria regardless of 5-HD pretreatment. At 1 minute after exposure to 3-NPA, TMRE was released into the cytoplasm and increased the fluorescence intensity at the whole cell level. TMRE fluorescence was redistributed into the mitochondria at 5 minutes after 3-NPA treatment. Pretreatment with 5-HD inhibited 3-NPA–induced alterations of TMRE fluorescence intensity in both cell types.

Additionally, 3-NPA induced increases in CMTMROS fluorescence intensity, which was inhibited by the preincubation of 5-HD, as shown in Figure 3C.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
In this study we provided the first evidence that administration of 3-NPA protects the brain in situ via mechanisms that involve activation of mitoKATP. The effects of 3-NPA in limiting infarct volume were not correlated with the restoration of local CBF during ischemia and were blocked by administration of 5-HD or glibenclamide. Furthermore, in cultured cells 3-NPA resulted in mitochondrial depolarization, and these effects were also blocked by 5-HD. In numerous studies, 5-HD has been used as a selective antagonist of mitoKATP.5,8–10 Recently, in heart, it was reported that 5-HD may also stimulate ß-oxidation.22 However, 3-NPA itself is reported to inhibit ß-oxidation in the central nervous system.23 Therefore, our present results using 5-HD, together with those involving glibenclamide administration, suggest a key role of mitoKATP as a trigger in the development of ischemic tolerance induced by 3-NPA in brain.

Systemic injection of 3-NPA 20 mg/kg IP has been shown to decrease succinate dehydrogenase enzymatic activity by 70% for several days, resulting in a decrease in brain ATP levels initially of up to 50%.3 Previously, glibenclamide has been reported to eliminate the 3-NPA–induced hyperpolarization of the cultured neuronal cells16 or prolongation of hypoxic depolarization in hippocampal slices.24 These findings agree with our results that glibenclamide abolishes the reduction of the infarct area after 3-NPA pretreatment. Therefore, like ischemic preconditioning, potassium channel activation is thought to play a key role in chemical preconditioning. Recent pharmacological studies revealed that glibenclamide inhibited not only sKATP but also mitoKATP.6 In the present study, to extend these important earlier findings, we report that selective blockade of mitoKATP prevents delayed chemical preconditioning with 3-NPA using an in vivo model. Similar results have recently been published for the heart.7 However, the precise details of this relationship among 3-NPA pretreatment, activation of mitoKATP, depolarization of mitochondria, and delayed protection against ischemic challenge are unclear.

In the present fluorescence experiments using TMRE, we showed that 300 µmol/L 3-NPA depolarized the mitochondria and that this effect was blocked with 5-HD. Similar responses were observed in astrocytes (data not shown). Since Riepe et al16 failed to show that single application of 0.1 to 10 mmol/L 3-NPA induced currents in the plasma membrane of cultured neurons, the increase of TMRE fluorescence intensity elicited by 300 µmol/L 3-NPA in our experiments suggested a direct effect on mitochondria. Our data with TMRE and CMTMROS indicate that the 3-NPA–induced changes in {Delta}{Psi}m were caused by opening of mitoKATP.

The mechanisms involved in the present chemical preconditioning remain obscure. Wiegand et al3 showed that administration of a free radical scavenger or protein synthesis inhibitor completely abolished chemical preconditioning with 3-NPA in brain. Additionally, Sugino et al25 demonstrated that preconditioning with 3-NPA activated c-jun N-terminal kinases (JNK) that induce transcriptional factors such as c-Jun or ATF2.26 In heart, recent studies showed free radical formation after activation of mitoKATP.27 Taken together, it is possible to speculate that mitoKATP opening leads to oxygen radical release, enhanced protein synthesis, and resultant ischemic tolerance. It is not clear at the present time which proteins are involved in development of preconditioning associated with 3-NPA, but such diverse proteins as the adenosine A3 receptor28 or anti-apoptosis proteins like bcl-215 have been suggested.

In our model, the chemical preconditioning conferred no protective effect on striatum despite its regional vulnerability to 3-NPA toxicity. This result is consistent with the previous data that ischemic preconditioning prevents neuronal injury in neocortex but not in subcortex after transient MCAO with the intraluminal thread model.29 Memezawa et al30 reported that selective neuronal necrosis in the caudoputamen was observed after only 15 minutes of MCAO, while neocortex was intact. Therefore, we believe that the limitation of 3-NPA–induced neuroprotection in striatum is due either to lack of collateral blood flow during MCAO or to increased vulnerability to ischemia in this region.

In conclusion, we have provided evidence to indicate that the activation of mitoKATP is involved in development of the delayed ischemic tolerance induced by a sublethal dose of the neurotoxin 3-NPA. We believe that mitoKATP is a novel target for study to clarify the mechanisms of endogenous protection from ischemia in brain.


*    Acknowledgments
 
This work was supported by grants HL30260, HL46558, and HL50587 from the National Institutes of Health and American Heart Association Bugher Foundation Award 0270114N. The authors would like to thank Ken Grant for excellent technical assistance in confocal microscopic experiments.

Received July 22, 2002; revision received October 9, 2002; accepted November 4, 2002.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 
1. Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H, Niinobe M, Handa N, Fukunaga R, Kimura K, Mikoshiba K, et al. ‘Ischemic tolerance’ phenomenon found in the brain. Brain Res. 1990; 528: 21–24.[CrossRef][Medline] [Order article via Infotrieve]

2. Yanamoto H, Hashimoto N, Nagata I, Kikuchi H. Infarct tolerance against temporary focal ischemia following spreading depression in rat brain. Brain Res. 1998; 784: 239–249.[CrossRef][Medline] [Order article via Infotrieve]

3. Wiegand F, Liao W, Busch C, Castell S, Knapp F, Lindauer U, Megow D, Meisel A, Redetzky A, Ruscher K, et al. Respiratory chain inhibition induces tolerance to focal cerebral ischemia. J Cereb Blood Flow Metab. 1999; 19: 1229–1237.[CrossRef][Medline] [Order article via Infotrieve]

4. Heurteaux C, Lauritzen I, Widmann C, Lazdunski M. Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K+ channels in cerebral ischemic preconditioning. Proc Natl Acad Sci U S A. 1995; 92: 4666–4670.[Abstract/Free Full Text]

5. O’Rourke B. Myocardial K(ATP) channels in preconditioning. Circ Res. 2000; 87: 845–855.[Abstract/Free Full Text]

6. Bajgar R, Seetharaman S, Kowaltowski AJ, Garlid KD, Paucek P. Identification and properties of a novel intracellular (mitochondrial) ATP-sensitive potassium channel in brain. J Biol Chem. 2001; 276: 33369–33374.[Abstract/Free Full Text]

7. Ockaili RA, Bhargava P, Kukreja RC. Chemical preconditioning with 3-nitropropionic acid in hearts: role of mitochondrial K(ATP) channel. Am J Physiol. 2001; 280: H2406–H2411.

8. Domoki F, Perciaccante JV, Veltkamp R, Bari F, Busija DW. Mitochondrial potassium channel opener diazoxide preserves neuronal-vascular function after cerebral ischemia in newborn pigs. Stroke. 1999; 30: 2713–2718;comment 2718–2719.

9. Shimizu K, Lacza Z, Rajapakse N, Horiguchi T, Snipes J, Busija DW. MitoK(ATP) opener, diazoxide, reduces neuronal damage after middle cerebral artery occlusion in the rat. Am J Physiol. 2002; 283: H1005–H1011.

10. Liu D, Lu C, Wan R, Auyeung WW, Mattson MP. Activation of mitochondrial ATP-dependent potassium channels protects neurons against ischemia-induced death by a mechanism involving suppression of Bax translocation and cytochrome c release. J Cereb Blood Flow Metab. 2002; 22: 431–443.[Medline] [Order article via Infotrieve]

11. Coles CJ, Edmondson DE, Singer TP. Inactivation of succinate dehydrogenase by 3-nitropropionate. J Biol Chem. 1979; 254: 5161–5167.[Free Full Text]

12. Alexi T, Hughes PE, Knusel B, Tobin AJ. Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALB/c ByJ mice. Exp Neurol. 1998; 153: 74–93.[CrossRef][Medline] [Order article via Infotrieve]

13. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci. 1993; 13: 4181–4192.[Abstract]

14. Riepe MW, Esclaire F, Kasischke K, Schreiber S, Nakase H, Kempski O, Ludolph AC, Dirnagl U, Hugon J. Increased hypoxic tolerance by chemical inhibition of oxidative phosphorylation: "chemical preconditioning." J Cereb Blood Flow Metab. 1997; 17: 257–264.[Medline] [Order article via Infotrieve]

15. Brambrink AM, Schneider A, Noga H, Astheimer A, Gotz B, Korner I, Heimann A, Welschof M, Kempski O. Tolerance-inducing dose of 3-nitropropionic acid modulates bcl-2 and Bax balance in the rat brain: a potential mechanism of chemical preconditioning. J Cereb Blood Flow Metab. 2000; 20: 1425–1436.[CrossRef][Medline] [Order article via Infotrieve]

16. Riepe M, Hori N, Ludolph AC, Carpenter DO, Spencer PS, Allen CN. Inhibition of energy metabolism by 3-nitropropionic acid activates ATP-sensitive potassium channels. Brain Res. 1992; 586: 61–66.[CrossRef][Medline] [Order article via Infotrieve]

17. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989; 20; 84–91.[Medline] [Order article via Infotrieve]

18. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab. 1990; 10: 290–293.[Medline] [Order article via Infotrieve]

19. Nishimura M, Takahashi H, Nanbu A, Sakamoto M, Nakanishi T, Yoshimura M. Cerebral ATP-sensitive potassium channels during acute reduction of carotid blood flow. Hypertension. 1995; 25: 1069–1074.[Abstract/Free Full Text]

20. Deadwyler SA, Hampson RE, Mu J, Whyte A, Childers S. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J Pharmacol Exp Ther. 1995; 273: 734–743.[Abstract/Free Full Text]

21. Hampson RE, Mu J, Deadwyler SA. Cannabinoid and kappa opioid receptors reduce potassium K current via activation of G(s) proteins in cultured hippocampal neurons. J Neurophysiol. 2000; 84: 2356–2364.[Abstract/Free Full Text]

22. Hanley PJ, Mickel M, Loffler M, Brandt U, Daut J. K(ATP) channel-independent targets of diazoxide and 5-hydroxydecanoate in the heart. J Physiol. 2002; 542: 735–741.[Abstract/Free Full Text]

23. Esfandiari A, Soifiyoudine D, Paturneau-Jouas M. Inhibition of fatty acid beta-oxidation in rat brain cultured astrocytes exposed to the neurotoxin 3-nitropropionic acid. Dev Neurosci. 1997; 19: 312–320.[Medline] [Order article via Infotrieve]

24. Nakagawa I, Nakase H, Aketa S, Kamada Y, Yamashita M, Sakaki T. ATP-dependent potassium channel mediates neuroprotection by chemical preconditioning with 3-nitropropionic acid in gerbil hippocampus. Neurosci Lett. 2002; 320: 33–36.[CrossRef][Medline] [Order article via Infotrieve]

25. Sugino T, Nozaki K, Hashimoto N. Activation of mitogen-activated protein kinases in gerbil hippocampus with ischemic tolerance induced by 3-nitropropionic acid. Neurosci Lett. 2000; 278: 101–104.[CrossRef][Medline] [Order article via Infotrieve]

26. Clerk A, Harrison JG, Long CS, Sugden PH. Pro-inflammatory cytokines stimulate mitogen-activated protein kinase subfamilies, increase phosphorylation of c-Jun and ATF2 and upregulate c-Jun protein in neonatal rat ventricular myocytes. J Mol Cell Cardiol. 1999; 31: 2087–2099.[CrossRef][Medline] [Order article via Infotrieve]

27. Yao Z, Tong J, Tan X, Li C, Shao Z, Kim WC, vanden Hoek TL, Becker LB, Head CA, Schumacker PT. Role of reactive oxygen species in acetylcholine-induced preconditioning in cardiomyocytes. Am J Physiol. 1999; 277: H2504–H2509.[Medline] [Order article via Infotrieve]

28. von ACA, Timmler M, Ludolph AC, Riepe MW. Adenosine receptor up-regulation: initiated upon preconditioning but not upheld. Neuroreport. 2000; 11: 1223–1226.[Medline] [Order article via Infotrieve]

29. Matsushima K, Hakim AM. Transient forebrain ischemia protects against subsequent focal cerebral ischemia without changing cerebral perfusion. Stroke. 1995; 26: 1047–1052.[Abstract/Free Full Text]

30. Memezawa H, Smith ML, Siesjo BK. Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats. Stroke. 1992; 23: 552–559.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
Physiol. Rev.Home page
T. P. Obrenovitch
Molecular Physiology of Preconditioning-Induced Brain Tolerance to Ischemia
Physiol Rev, January 1, 2008; 88(1): 211 - 247.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
S. Roth, J. C. Dreixler, A. R. Shaikh, K. H. Lee, and V. Bindokas
Mitochondrial Potassium ATP Channels and Retinal Ischemic Preconditioning
Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 2114 - 2124.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Turan, C. Csonka, T. Csont, Z. Giricz, G. Fodor, P. Bencsik, M. Gyongyosi, I. Cakici, and P. Ferdinandy
The role of peroxynitrite in chemical preconditioning with 3-nitropropionic acid in rat hearts
Cardiovasc Res, May 1, 2006; 70(2): 384 - 390.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. Mabanta, P. Valane, J. Borne, and M. D. Frame
Initiation of remote microvascular preconditioning requires KATP channel activity
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H264 - H271.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
B. O'Rourke
Evidence for Mitochondrial K+ Channels and Their Role in Cardioprotection
Circ. Res., March 5, 2004; 94(4): 420 - 432.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
34/4/1015    most recent
01.STR.0000063404.27912.5Bv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Horiguchi, T.
Right arrow Articles by Busija, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horiguchi, T.
Right arrow Articles by Busija, D. W.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*3-NITROPROPIONIC ACID
Medline Plus Health Information
*Transient Ischemic Attack
Related Collections
Right arrow Animal models of human disease
Right arrow Acute Cerebral Infarction
Right arrow Neuroprotectors